Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › REDEFINE 3

REDEFINE 3

CagriSema · Obesity + established CVD

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
CagriSema
Population
Obesity + established CVD
Official title
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
Sponsor
Novo Nordisk A/S
Phase
Phase 3
Registry status
active not recruiting · 2023-03 → 2027-09
Participants
7101
Registry
NCT05669755

Ongoing outcome trial

TrialMoleculePopulationPrimary endpointnRegistry statusPrimary completionRegistry
REDEFINE 3CagriSemaObesity + established CVD
Obesity + established CVD, with or without T2D
3-point MACE7101active not recruiting2027-09-01NCT05669755

No results yet; the primary completion date comes from the registry.

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: REDEFINE 3. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-3/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.